Medelinked is the First Application to Feature in BioClinica’s App xChange
News Sep 16, 2015
Medelinked has announced that it will be the first application featured in the BioClinica®, eHealth App xChange™, an alliance channel for disruptive technology innovation across life sciences and healthcare.
Medelinked allows individuals to use mobile technology and the cloud to increase the effectiveness of health care by enabling them to securely build their health profile online and to connect and share with their network of trusted health partners.
Pennsylvania -based BioClinica, a global specialty clinical trials technology and services provider that serves more than 400 pharmaceutical, biotechnology, and device organizations, recently launched the eHealth App xChange. It provides healthcare payers, providers, researchers, regulators and patients with access to transformative applications integrated with and delivered through BioClinica’s eHealth Cloud™.
Leading innovation in regulated clinical trials
BioClinica eClinical President, Mukhtar Ahmed says: "Our App xChange is an incubator and growth engine for niche technology providers and individual app developers, so we welcome Medelinked as the first in a series of new partners as BioClinica continues to lead industry innovation within the regulated clinical trial space."
Ahmed continues: "Medelinked’s presence in the App xChange will enable research communities to ensure unique levels of patient and consumer engagement so accelerating pre- and post-approval research while creating efficiency and quality benefits."
Driving the global shift in how patients and the healthcare industry connect
Ian Gallifant, Medelinked founder and CEO, says: “With this latest development, Medelinked is further driving the global shift in how patients and the healthcare industry connect from early clinical research and trials right through to day-to-day health management. The fact that BioClinica has chosen Medelinked to be the first to feature on its new strategic and disruptive platform is a profound endorsement of the quality and effectiveness of Medelinked’s technology.”
Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line TreatmentNews
The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.READ MORE
Diabetes Drug Could Be Re-purposed to Help End Transplant RejectionNews
A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs.READ MORE
Study Shows Cancer Patients Are Choosing Less Severe Side Effects Over Treatment EfficacyNews
When choosing their preferred treatment, people with chronic lymphocytic leukemia (CLL) place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for a reduced risk of serious adverse events according to a new study.READ MORE